|
BTG LICENSES BARNES & NOBLE TO ITS ONLINE NAVIGATION TRACKING PATENTS
30 September 2006 - BTG
| BTG announces it has reached a settlement with BarnesandNoble.com over a patent infringement lawsuit filed by BTG. The financial terms of the settlement with Barnes & Noble are undisclosed. As a result of this settlement, BTG has dismissed its claims and granted Barnes & Noble a non-exclusive license to patents covering technology for tracking the navigational path of a user through the World Wide Web. |
BTG announces it has reached a settlement with BarnesandNoble.com over a patent infringement lawsuit filed by BTG. The financial terms of the settlement with Barnes & Noble are undisclosed. As a result of this settlement, BTG has dismissed its claims and granted Barnes & Noble a non-exclusive license to patents covering technology for tracking the navigational path of a user through the World Wide Web. BTG dismissed similar claims against co-defendant, Netflix, Inc., who also took a license to the patents. BTG's suit continues to be pursued against two remaining defendants - Amazon.com and Overstock.com Louise Makin, Chief Executive Officer of BTG, commented: "We are very happy to have reached an agreement with Barnes & Noble and we are pleased with the ongoing success of our licensing efforts for these patents." BTG filed suit in Federal Court in Delaware against Amazon.com, BarnesandNoble.com, Netflix and Overstock.com for infringement of patented technology that enables efficient tracking of the movement of Internet users between websites and is used in certain online marketing programs.
http://www.btgplc.com
About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively. |
More News:
• For September 2006
• From BTG
• For Polymer OLED Devices
|
